Revance Therapeutics | 销售和管理费用



Selling And Administration Expenses 更改 日
AbbVie USD 3.29B 562M 2025-03
ALKERMES USD 171.7M 24.71M 2025-03
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Eli Lilly USD 2.36B 62.3M 2025-03
J&J USD 5.11B 1.34B 2025-03
Merck USD 2.53B 319M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
P&G USD 5.5B 225M 2025-03
Pacira USD 86.78M 7.16M 2025-03
Supernus Pharmaceuticals USD 79.41M 9.66M 2024-12



Revance Therapeutics 销售和管理费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Jul 2025.